Neurotech International (ASX:NTI) said the 28-day good laboratory practice oral toxicology studies in rats and dogs evaluating its NTI164 drug candidate demonstrated excellent tolerability and no safety concerns, according to a Monday Australian bourse filing.

The animals received twice-daily oral dosing across low, mid, and high dose levels, followed by a 14-day recovery period.

It said that no test article-related adverse effects were observed across clinical observations, ophthalmic exams, neurological assessments, or clinical pathology.

The firm is focused on treating paediatric neurological disorders via the NTI164 broad-spectrum oral cannabinoid drug therapy candidate.

Its shares rose 9% on Monday's close.